Polymyalgia Rheumatica Disease (PMR)

Published Date : Nov 2023
Category : Cardiovascular Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

A Detailed Polymyalgia Rheumatica Disease Report

Polymyalgia rheumatica (PMR) is a relatively common yet often neglected inflammatory disorder that primarily affects older adults. PMR significantly impacts an individual's quality of life, and early diagnosis and appropriate management are essential to relieve symptoms and prevent complications.

DiseaseLandscape Insights services provide an overview of PMR, including its pathophysiology, diagnostic criteria, treatment options, recent developments in research, market trends, and clinical trial assessment.

PMR is more prevalent among Caucasians than in other racial groups, and it affects women more frequently than males. It is unusual in those under 50 and usually manifests by the time one is 70 years old. PMR varies from person to person and lasts anywhere from one to five years. Giant cell arteritis (GCA), a potentially fatal illness, affects around 15% of individuals with PMR.

An inflammatory condition known as polymyalgia rheumatica (PMR) is characterized by widespread pain, stiffness, and flu-like symptoms. The general symptoms include depression, hip pain, neck pain, bilateral shoulder pain, morning stiffness, symmetrical pain, fatigue, and weakness. However, the severity and intensity of PMR disease vary from person to person

Although the specific cause of PMR is unknown, it is thought to be an autoimmune condition in which the body's defenses target healthy tissues. It is believed that both genetic and environmental factors—such as infections—play significant roles. Given that it is uncommon in those under 50, aging may be a contributing factor.

According to an NIH report, the yearly incidence of polymyalgia rheumatica per 100,000 people over the age of 50 was observed to range between 58 and 96 in mostly white communities. Incidence rates rise with age until the age of 80. However, PMR is not common in Black, Asian, and Hispanic people.

Moreover, PMR aggregation in families has shown a hereditary susceptibility. PMR is connected with HLA class II alleles, with the HLA-DRB1*04 allele correlating most commonly, appearing in up to 67% of cases as stated in the NIH report. In some groups, genetic polymorphisms for ICAM-1, RANTES, and IL-1 receptors appear to have a role in the development of PMR.

However, there have been recent reports of increased PMR and GCA incidence during outbreaks of mycoplasma pneumonia and parvovirus B19 in Denmark, indicating that infection plays a role in etiopathogenesis. The Epstein-Barr virus (EBV) has also been postulated as a potential PMR cause.

To reduce PMR disease outbreaks, many sectors must collaborate to develop and implement the necessary technology and resources. Public health authorities, pharmaceutical companies, healthcare organizations, and other stakeholders must work together to guarantee a willing and timely response to PMR outbreaks.

Because of the high incidence and fatality rate from PMR, the lack of early diagnostic kits, and the lack of comprehensive curative therapy and medicine, the market for PMR is constantly rising. Finding the specific etiology and identification of PMR is another issue influencing the PMR industry.

All of the ways outlined above encourage major actors to conduct targeted research in the field of PMR therapy and diagnosis. However, such prospects generate numerous opportunities for new industry participants to enter and build their enterprises.

The worldwide transmission of the PMR disease has had a significant influence on people's quality of life.  With the help of DiseaseLandscape Insights in the area of bone disease, the current state of the PMR disease market would expand in healthcare sectors in the right direction and give growing prospects for a variety of market players.

In this collaborative ecosystem, we enhance public health, minimize disease effects, and strive toward the ultimate objective of eliminating PMR. DiseaseLandscape Insights enables all industry players to identify the best area in which to expand and build a successful business in the treatment and diagnostic domains of PMR.

Diagnostic Analysis of Polymyalgia Rheumatica

“Detecting Polymyalgia Rheumatica with Definitive Diagnostic Techniques”

Diagnosis of Polymyalgia rheumatica is initiated with the physical exam and joint and neurological exam of patients. These tests help physicians to determine the cause of symptoms and rule out other diseases. After that following tests are performed to completely and correctly diagnose the Polymyalgia rheumatica.

  • Blood Tests

Blood tests were performed to check the level of WBCs, erythrocyte sedimentation rate (ESR), and C - C-reactive protein (CRP) in the sample of the patient.

Increased ESR level is a characteristic of polymyalgia rheumatica. The majority of professionals consider ESR more than 40 mm to be noteworthy. According to the NIH, ESR less than 40 mm/h is found in 7% to 20% of PMR individuals.

CRP is also commonly high in PMR patients. In one study, CRP was shown to be a more sensitive sign of disease activity, although ESR was found to be a better predictor of relapse.

  • Imaging Tests

Imaging tests including ultrasound, magnetic resonance imaging, and positron emission tomography are used to diagnose the PMR.

In PMR patients, ultrasound helps with diagnosis and therapy by measuring degrees of subacromial/subdeltoid bursitis, lengthy head biceps tenosynovitis, and glenohumeral synovitis.

MRI, like ultrasound, helps to display bursitis, synovitis, and tenosynovitis; however, it is more sensitive to hip and pelvic girdle abnormalities. Pelvic MRI typically reveals bilateral peri-tendinous enhancement of pelvic girdle tendons, as well as the presence of low-grade hip joint inflammation. A rectus femoris proximal origin supplementation is a precise and sensitive observation.

In individuals with PMR, PET scans demonstrate FDG uptake in the shoulders, ischial tuberosities, greater trochanters, and glenohumeral, and sternoclavicular joints. As per  the NIH, a PET/CT scan revealed large vessel vasculitis in 60.7% of patients with PMR who had a persistent episode of typical symptoms but no cranial GCA-like symptoms.

PMR is diagnosed using a number of approaches, including blood testing for various biomarkers and imaging studies. The availability of resources, the location of the facility, and the particular purposes of the diagnosis, such as direct patient care or epidemiological study, all influence the choice of a diagnostic procedure. Accurate and timely diagnosis is required to provide appropriate treatment and management of PMR outbreaks.

Because there is no gold standard test for PMR, physicians must depend on current categorization criteria, laboratory results, and response to treatment to reach a diagnosis, although the primary characteristics of the disorder are still debated.

DiseaseLandscape Insights contributes to industry leaders with the launching of various diagnostic kits, the use of novel technologies for enhancing existing diagnostic methods, and the supply of insights on current market participants and their products to get a better understanding of market dynamics. DLI services assist businesses in navigating the complex requirements of the industry, being competitive, and contributing to public health through enhancing and elevating PMR diagnosis.

The below table shows the names of trending market players involved in the PMR diagnostic sector.

                                                                               Diagnostic Market Players

Blood Tests

Imaging Tests

Quest Diagnostics

GE Healthcare

LabCorp (Laboratory Corporation of America)

Siemens Healthineers

Roche Diagnostics

Philips Healthcare

Abbott Laboratories

Toshiba Medical Systems

Siemens Healthineers

Fujifilm Medical Systems

Bio-Rad Laboratories

Shimadzu Medical Systems


Carestream Health




The below table lists the names of innovative and evolutionary products that are promoting the health of patients.

                                                                             Diagnostic Products

Blood Tests

Imaging Tests

StatStrip Xpress®2



Row CT Scanner

Isoton III®



Flash CT Scanner



Latron® Primer




Treatment Analysis of Polymyalgia Rheumatica

“Evolution of Treatment Advancements for Better Patient’s Health”

The treatment of polymyalgia rheumatica includes various medications that help to relieve the symptoms and prevent complications in the patients. The following are the treatment options available in the market to manage and treat the Polymyalgia rheumatica.

  • Corticosteroids

An oral corticosteroid, such as prednisone (Rayos), is often used in small doses to treat polymyalgia rheumatica. Within the first two or three days, pain and tightness should start to diminish. Depending on symptoms and the outcomes of blood tests, doctors decide to gradually reduce dosage after the first two to four weeks of treatment.

However, serious adverse effects from long-term corticosteroid treatment include weight gain, low bone density, high blood pressure, diabetes, and cataracts.

  • Calcium and Vitamin D

For the purpose of preventing bone loss induced by corticosteroid therapy, the doctor would generally recommend regular dosages of calcium and vitamin D supplements. When using corticosteroids for three months or more, the American College of Rheumatology suggests taking 1,000–1,200 mg of calcium supplements and 600–800 international units of vitamin D supplements.

  • Methotrexate

According to joint guidelines from the European League Against Rheumatism and the American College of Rheumatology, some individuals would benefit from corticosteroids in addition to methotrexate (Trexall). This drug suppresses the immune system and is administered orally. If a patient relapses or doesn't react to corticosteroids, it is helpful early in the course of treatment or later on.

DiseaseLandscape Insights assists the market player in changing and growing within the Polymyalgia rheumatica treatment domain in order to enhance patient retention, investigate novel treatment approaches, and reach new socioeconomic heights.

With our in-depth examination of treatment alternatives, service contributions, product inventories, and market competitiveness, DLI provides market participants with the tools they need in order to remain one step ahead of the competition. As a committed partner to the pharmaceutical industry, we deliver comprehensive assistance in planning, conducting, and assessing clinical trials for the creation of innovative new medications.

The worldwide market for polymyalgia rheumatica is highly fragmented and owes a prominent market player with a global presence. The market leaders in the table below are reinventing the domain and pushing innovation to achieve better health outcomes.

Treatment Market Players



Kevzara® (sarilumab)


Sarilumab (Kevzara)


Tocilizumab (Actemra)

GlaxoSmithKline (GSK)



Prednisone (Deltasone)

Horizon Pharma

Prednisone (Rayos)

Eon Labs, Inc.

Prednisone (Orasone)


Market Trends

“A Deep Evaluation of Market Trends of Polymyalgia Rheumatica to Sustain in the Business”

Market trends for medical disorders such as Polymyalgia Rheumatica (PMR) alter over time due to a number of reasons such as improvements in treatment methods, modifications in medical research, and changes in the demography of afflicted populations.

However, it is necessary that patients and healthcare providers become up-to-date on the most recent advancements in PMR research and management.

Moreover, the application of ultrasonography in the diagnosis of PMR has gained increasing attention. Rheumatologists and radiologists have been the main image-capture specialists in studies. PMR has been linked to a range of intra- and extra-articular ultrasonographic abnormalities, such as synovitis, bursitis, and biceps tenosynovitis. The key players would generate huge business from the ultrasonography sector.

Research and clinical trials result in the discovery of novel treatment alternatives or the improvement of current treatments. A possible trend is reducing dependence on high-dose corticosteroids and researching other medicines with less adverse effects. Industry players have tremendous scope in the field of the treatment industry of PMR. Entering into this field and launching new products will enhance the overall capital of the company.

Furthermore, there is continuing research into the use of biologics and targeted treatments in the treatment of autoimmune diseases such as PMR. As a result, therapy procedures become more specific and efficient. Stakeholders should do concentrated research on biologics and targeted treatments and launch novel products in the market. This opportunity helps the company to grow in the global market and sustain in competitive edge.

The cost of therapies and availability of care are significant problems in PMR management. These variables influence therapy selection and patient outcomes. So, there is a need for market players to look into cost factors during the development of any therapy and diagnostic techniques. The creation of low-cost and highly effective treatment medications and diagnostic kits is the area where leading players should concentrate on expanding their business across the globe.

Regulatory Framework for Polymyalgia Rheumatica

“Reviewing Regulatory Approval: Deciding Plan of Action for Better Business”

The regulatory framework governing the PMR business is critical for maintaining patient safety, treatment efficacy, and market integrity. Regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have set extremely high standards for the licensing of PMR-related drugs, therapies, and medical devices.

Furthermore, regulatory organizations have set requirements for both healthcare practitioners and the general public in terms of precise diagnosis, sufficient labeling, and clear communication of potential risks and benefits.

The FDA has authorized Kevzara® (sarilumab) for the treatment of polymyalgia rheumatica (PMR), an inflammatory rheumatic illness, in adult patients who have had an insufficient response to corticosteroids or who cannot tolerate corticosteroid taper, on February 28th, 2023.

DiseaseLandscape Insights provides detailed guidance as well as ideas for dealing with polymyalgia rheumatica disease. To preserve public health, all stakeholders must become acquainted with this framework and operate by its principles. Exploring the DiseaseLandscape Insights services enables organizations and market participants to avoid, manage, and respond to PMR flare-ups, as well as preserve the safety of afflicted people.

Competitive Analysis

 “The Strategies of Companies: Way for Standard Business Establishment”

The fiercely competitive environment of the PMR disease market reflects the dynamic relationship between pharmaceutical companies, medical device developers, and diagnostic suppliers. Major industry participants are deeply focused on research and development projects in order to create cutting-edge treatment solutions with greater efficacy and fewer adverse effects.

As a result of this effort, novel medication formulations like as biologics, personalized medicines, and targeted therapies have evolved, and they are currently competing for market share.

Along with pharmaceutical improvements, diagnostic businesses are making major contributions to the sector by developing sophisticated tests that assist in the correct diagnosis and division of PMR.

Competitors like Roche, AbbVie, Sanofi, Pfizer, Novartis, and so on are working on the treatment and diagnostic field of autoimmune diseases like polymyalgia rheumatica. These companies are researching the underlying cause and pathophysiology of PMR disease. Investigation of new biomarkers, and studies on the impact of treatment on the outcome of patients to launch novel treatment options in the market.

The inventions and product developments by such companies have increased the awareness of PMR in the general public along with the product awareness. The research and developments in the PMR sectors have increased the collaborations of the companies. Marketing of novel products has increased the overall revenue of the companies and innovations have set the standard for other key players.

Clinical Trial Assessment

The growing focus of the government on comparing study efficacy underscores the critical role that clinical trials play in evidence-based medicine and healthcare reform. By using clinical data, market players appropriately assess medical therapy, which is one of the key aims of healthcare reform.

The ongoing clinical trials' study names and the titles of stages II, III, and IV at which they are being conducted are shown in the table below.

Phase II

Phase III

Phase IV

A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects with Polymyalgia Rheumatica (PMR).

Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse

RESCUE - Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency; A Multicentre, Randomised, Double Blinded, Placebo-controlled Clinical Trial on Health-related Quality of Life in Patients With Polymyalgia Rheumatica/Giant Cell Arteritis Receiving Ongoing Low-dose Prednisolone Treatment.

BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica (BACHELOR Study).

Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica


A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Methotrexate as Remission Maintenance Therapy After Remission-Induction Therapy With Tocilizumab and Glucocorticoids in Subjects With Giant Cell Arteritis

A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg and 150 mg Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) (GCAptAIN)


Evaluating the Use of Gallium-68 HA-DOTATATE Positron Emission Tomography/Computerized Tomography (PET/CT) in Patients With Giant Cell Arteritis (GCA.)

A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Efficacy and Safety of Subcutaneously Administered Secukinumab in Patients With New-onset of Giant Cell Arteritis (GCA) Who Are in Clinical Remission and Eligible for Treatment With Glucocorticoid-monotherapy


Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis

Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement (ToGiAC)


Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial




DiseaseLandscape Insights (DLI) helps the industry by expediting patient recruitment, clinical trial protocols, and regulatory compliance for new medicines. DLI contributes to the objective of the healthcare industry of developing breakthrough technologies that radiate commercial potential in the portfolio of PMR therapies.

DLI services intend to assess the burden caused by the PMR condition by considering a variety of factors that suggest future market trends for pharmaceutical companies conducting research & development for PMR diagnostic tools and medications.

DiseaseLandscape Insight disseminates market analysis and business insights developed by highly trained and informed industry analysts. Our research publications span a wide range of disease categories, including infectious sickness, chronic disease, genetic disease, autoimmune disease, mental health problems, and environmental disease.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape